CETP and metabolic dysfunction-associated steatotic liver disease: Our results showed that plasma activity of cholesterylester transfer protein (CETP) increased in NAFLD patients (33.34 ± 6.86 nmol/mL/h) compared to controls (29.50 ± 7.05 nmol/mL/h, P = 0.017) (Fig. 1d), but there was no significant difference in the activities of phospholipid transfer protein (PLTP) and lecithin–cholesterol acyltransferase (LCAT) between the two groups (Fig. 1e,f).